Five years on from the FDA enforcement-discretion window closing, the cell-free, autologous, minimally manipulated end of regenerative-medicine research is no longer the fringe conversation it once was. The peer-reviewed publication record on extracellular vesicles and secretome-derived preparations has continued to expand, the regulatory framework around Section 361 eligibility has matured, and the broader operator landscape has settled into a more professional shape than it had five or six years ago.
The growth of the formal research record is the most visible change. The number of peer-reviewed publications on extracellular-vesicle and secretome-derived preparation has grown roughly tenfold across the 2015 to 2025 decade. The research is no longer concentrated in a small number of laboratories. It is being done across academic, clinical, and commercial settings on multiple continents. The methodological standards, including the characterisation and quality-control conventions that any credible programme operates under, have tightened considerably.
The regulatory environment has continued to develop. The FDA’s November 2017 framework remains the structural reference point. Subsequent guidance from the agency has clarified specific application areas and specific preparation methods. Other major regulatory environments, including the European Medicines Agency, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, and the regulatory bodies in Japan, Singapore, and Australia, have all developed their own frameworks for autologous cell and tissue products. The frameworks differ in detail but agree in their basic principle: autologous, minimally manipulated, homologous-use preparations sit under a lighter regulatory framework, with anything that fails those tests requiring full premarket approval.
The operator landscape has also become more professional. The unregulated end of the field, in which clinics offered loosely characterised stem-cell preparations for a wide range of claimed indications without meaningful oversight, has shrunk significantly. Most of the worst operators have been the targets of FDA enforcement action or equivalent regulatory action in their own jurisdictions. The signal-to-noise ratio in the public conversation about regenerative medicine has improved as a result, although the field still carries reputational weight from the period when that was not true.
Several unresolved questions remain in the field, and they are worth naming honestly. The field still lacks a fully standardised method for characterising the active components of secretome preparations across laboratories. Two preparations of nominally similar source material can differ substantially in their composition depending on preparation method, and the field has not yet converged on a single characterisation framework. Standards are tighter than they were a decade ago. They are not as tight as they need to be.
Long-term outcome data on cell-free, autologous interventions is also uneven. In some application areas the published evidence base is substantial. In others it is thin. Wellbeing’s own working position is that patient-observation data, accumulated over years and decades, is one of the most useful sources of evidence in this field, alongside the formal peer-reviewed research record. Both have limitations. Both are necessary.
The line between minimally manipulated preparations and culture-expanded products continues to be redrawn as new processing methods emerge. The FDA has issued additional guidance to clarify specific cases. The agency’s working position has remained consistent: the four criteria of Section 361 eligibility are not negotiable, and the question of whether any specific preparation method satisfies them is a technical question to be answered on the technical merits.
For Wellbeing specifically, the year ahead is about depth rather than reach. Tighter characterisation. Longer follow-up. More careful documentation. Continued engagement with the clinical networks that already work alongside the programme. The white-paper series being published through 2026 is the principal external expression of that depth-rather-than-reach orientation. Wellbeing does not consider itself in a race with other operators in the space, and treats the work as a long, slow accumulation of evidence rather than a competitive sprint.
Readers who want to follow the wider field across 2026 should track the publication record in journals that have historically covered cell-free preparation work, including Stem Cells International, Stem Cell Research and Therapy, and the Journal of Extracellular Vesicles. The FDA’s ongoing guidance issuance is the principal regulatory reference point. Industry conferences and academic-clinical convening events through the year are useful for understanding how the field is thinking about its open questions. Wellbeing does not consider itself uniquely positioned to comment on the field as a whole; it has its own view, which is the view of one careful operator in one specific corner of the space.